Latest studies
- RecruitingPHASE3
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
This study looks at a new medicine called obrixtamig for advanced small cell lung cancer. It compares obrixtamig plus standard treatment against standard treatment alone to see if it helps people live longer. It also tests a device to measure a cancer marker.
Small Cell Lung Cancer (SCLC)Extensive-stage Small Cell Lung Cancer (ES-SCLC)Ireland - Active not recruitingPHASE3
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
This study looks at the best treatment for women with a common type of early breast cancer. It compares hormone therapy alone against hormone therapy plus chemotherapy, using a special test to help decide which is best for each woman.
Breast AdenocarcinomaHormone Receptor PositiveStage IA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Ireland - RecruitingPHASE3
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
This study looks at a new drug, upadacitinib, for moderate to severe Hidradenitis Suppurativa (HS). It's for adults and teenagers whose HS hasn't improved with other treatments. We'll check if it's safe and helps reduce HS symptoms.
Hidradenitis SuppurativaIreland - Enrolling by invitationPHASE3
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
This study looks at a new medicine called efgartigimod for people with certain muscle conditions like myositis. It's for adults who were in a previous study, to see if the medicine is safe and helpful over a long time.
MyositisActive Idiopathic Inflammatory MyopathyDermatomyositisPolymyositisIreland - RecruitingPHASE3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
This study is looking into a new drug, AZD5335, for women with advanced ovarian cancer that has become resistant to usual chemotherapy. It compares AZD5335 to existing treatments to see if it works better at controlling the cancer's growth.
Epithelial Ovarian CancerIreland - Recruiting
EXtubation Related Complications - the EXTUBE Study (EXTUBE)
This study looks at issues that can happen when breathing tubes are removed after surgery or critical illness. Researchers want to understand why these problems happen and how medical teams can improve this common procedure to make it safer for everyone.
ExtubationIreland - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
This study is for people with advanced HR+/HER2- breast cancer. It compares a new drug, sacituzumab tirumotecan (alone or with pembrolizumab), against standard chemotherapy, to see which treatment best controls the cancer's growth.
Breast NeoplasmsIreland - RecruitingPHASE2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
This study is testing a new drug, nemtabrutinib, for people with certain blood cancers like lymphoma and leukaemia. It aims to see if the drug is safe and effective in treating these conditions.
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins LymphomaChronic Lymphocytic LeukaemiaIreland - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
This study is for women with cervical cancer that has spread. It's testing new combinations of medicines (sac-TMT, pembrolizumab, and possibly bevacizumab) to see if they are safe and can help people live longer or stop their cancer from getting worse.
Cervical CancerIreland - RecruitingPHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
This study is looking at an experimental drug called Pumitamig, by itself or with other treatments, for people with advanced kidney cancer (renal cell carcinoma). Researchers want to see how safe and effective these treatments are.
Advanced Renal Cell Carcinoma (RCC)Ireland - RecruitingPHASE3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
This study is looking at two different treatments, pumitamig and durvalumab, for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that can't be removed by surgery. It's for patients who have already had chemotherapy and radiation.
Non-small Cell Lung Cancer (NSCLC)Ireland - RecruitingPHASE3
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
This study is for women with advanced ovarian cancer that has responded well to initial treatment. It's testing a new medicine called sac-TMT, sometimes with bevacizumab, to see if it can keep the cancer from growing or coming back for longer than standard care.
Ovarian NeoplasmsOvarian CancerIreland - RecruitingPHASE3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
This study compares new ways to treat advanced lung cancer. It looks at two drug combinations, Nivolumab and Relatlimab plus chemotherapy, versus Pembrolizumab plus chemotherapy. The goal is to find the best treatment for a specific type of lung cancer.
Non-small Cell Lung CancerIreland - RecruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
Non-small Cell Lung CancerNSCLCIreland - RecruitingPHASE3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This study is looking at a new drug, camizestrant, for people with a common type of early breast cancer. It aims to see if camizestrant, compared to usual hormone therapy, can better prevent the cancer from coming back.
Breast Cancer, Early Breast CancerIreland - Active not recruitingPHASE2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
This study is testing a new medicine, Verekitug, for people with moderate to severe COPD. It will check how well the medicine works and if it's safe. Participants will take Verekitug or a dummy pill alongside their usual COPD treatments.
Chronic Obstructive Pulmonary DiseaseIreland - RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLCNSCLC (Non-small Cell Lung Carcinoma)Ireland - RecruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
This study looks at a new drug combination, sacituzumab tirumotecan and pembrolizumab, for a type of breast cancer called triple-negative. It's for patients who had initial treatment but still have some cancer cells after surgery. We want to see if this new combination helps prevent the cancer from coming back better than standard care.
Triple-Negative Breast CancerIreland - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
This study looks at a new treatment called sacituzumab tirumotecan, sometimes with another medicine called bevacizumab. We want to see if it's safe and helps women with ovarian, fallopian tube, or primary peritoneal cancer live longer without their cancer getting worse, compared to standard care.
Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerIreland - RecruitingPHASE4
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This study looks at the long-term safety of a medicine called pirtobrutinib for people with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It's for those already taking part in a previous pirtobrutinib study, to continue treatment and monitoring.
Chronic Lymphocytic LeukemiaLymphoma, Small LymphocyticIreland - RecruitingPHASE3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
This study compares a new medicine, INCB123667, with standard chemotherapy for women with ovarian cancer that has grown despite platinum-based treatment and shows specific genetic changes. It aims to see if the new drug works better than current options.
Ovarian CancerIreland - RecruitingPHASE2, PHASE3
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
This study is testing a new medicine, povetacicept, for people with a kidney condition called primary membranous nephropathy (pMN). It aims to see how well it works, if it's safe, and if people can tolerate it compared to another treatment, tacrolimus.
Primary Membranous NephropathyIreland - RecruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
This study looks at new treatments for a type of womb cancer that has spread or returned. It compares a new drug combination (sac-TMT with pembrolizumab) against pembrolizumab alone to see if it helps patients live longer and keeps the cancer from growing.
Endometrial CancerIreland - Active not recruitingPHASE3
REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
This study, called REDEFINE 3, investigates a new medicine, CagriSema, for people with heart and blood vessel diseases. It aims to see if CagriSema can reduce the risk of serious events like heart attacks and strokes.
Cardiovascular DiseaseIreland - RecruitingPHASE2
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis
This study is testing a new medicine, Vamifeport, for people with a common type of iron overload called hereditary hemochromatosis. It aims to see if the medicine can reduce the amount of iron stored in the liver. Two groups will be compared: one getting the medicine and one getting a dummy pill.
Homeostatic Iron Regulator Gene-related Hereditary HemochromatosisIreland - RecruitingPHASE3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
This study is testing a new medicine, ifinatamab deruxtecan (I-DXd), for men with advanced prostate cancer that has spread and isn't responding to hormone therapy. We want to see if I-DXd helps men live longer and keeps their cancer from growing compared to standard chemotherapy.
Prostate CancerProstatic NeoplasmsIreland - RecruitingPHASE3
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
This study is looking at a new medicine called axatilimab, alongside standard steroids, for people with chronic graft-versus-host disease (cGVHD). It compares axatilimab with a dummy medicine (placebo) to see how well it works to treat this condition.
Chronic Graft-versus-host-diseaseIreland - Recruiting
Product Surveillance Registry
This study keeps track of how well Medtronic medical devices, like those for heart problems or other conditions, work in real life. It aims to make sure these devices are safe and effective for patients.
Cardiac Rhythm DisordersUrological DisordersNeurological DisordersCardiovascular DisordersIreland - RecruitingPHASE3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
This study is testing a new medicine, Sofetabart Mipitecan, for certain ovarian, fallopian tube, and peritoneal cancers. It aims to see if it works better than current treatments and is safe, for people whose cancer either has or hasn't responded well to previous platinum-based treatments.
Ovarian NeoplasmsFallopian Tube NeoplasmsPeritoneal NeoplasmsNeoplasm MetastasisIreland - RecruitingPHASE2, PHASE3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
This study looks at a new drug, ficerafusp alfa, combined with pembrolizumab (Keytruda®) for people with advanced head and neck cancer. It compares this combination against pembrolizumab alone to see if it works better and is safe.
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaIreland - RecruitingPHASE1, PHASE2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
This study is testing new treatments, alone or in combination, for advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to see if these treatments are safe and effective in helping men with this condition.
Castration-Resistant Prostatic CancerMetastasisIreland - RecruitingPHASE2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
This study compares two treatments for a fast-growing blood cancer called diffuse large B-cell lymphoma (DLBCL), specifically a type called GCB DLBCL. Researchers want to see if a new drug, zilovertamab vedotin, when combined with standard therapy, works better than another combination in shrinking the cancer.
Lymphoma, Large B-Cell, DiffuseIreland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
This study looks at a new drug, pembrolizumab (Keytruda), combined with another medicine, enzalutamide. It's for men with advanced prostate cancer that has spread and isn't responding to hormone treatment. We want to see if this combination helps men live longer and slows down the cancer's growth.
Metastatic Castration-Resistant Prostate CancerIreland - Ongoing, recruitingTherapeutic use (Phase IV)
An 18-month low-interventional prospective, multicentre study to assess joint outcomes in patients with haemophilia A or B on prophylaxis with efmoroctocog alfa or eftrenonacog alfa
This study looks at how well different medicines (Elcocta and Alprolix) help people with haemophilia A or B protect their joints. Researchers will follow participants for 18 months to see if these treatments prevent joint problems.
Hemophilia A and BIreland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)
This study is testing a new medicine, secukinumab, for polymyalgia rheumatica (PMR). It compares secukinumab with a dummy treatment (placebo) alongside a common steroid medicine to see if it helps reduce symptoms and allows people to use less steroid medicine.
Polymyalgia RheumaticaIreland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension
This study looks at how long a special eye drop called Bimatoprost SR works for people with glaucoma or high eye pressure. It helps us understand if it keeps working over time to protect your eyesight.
Open-Angle Glaucoma, Ocular HypertensionIreland - Active not recruitingPHASE3
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
This study is looking at a new treatment called Tarlatamab for advanced small cell lung cancer that has come back after earlier treatment. We want to see if Tarlatamab helps people live longer compared to standard chemotherapy.
Small Cell Lung Cancer (SCLC)Ireland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
This study is testing if adding a new drug, pembrolizumab (Keytruda), to standard chemotherapy before and after surgery can help people with a type of bladder cancer. Researchers want to see if this combination works better than chemotherapy alone to keep the cancer away.
Cis-eligible Muscle-invasive bladder cancer.Ireland - Active not recruitingPHASE3
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
This study is testing a new combination treatment for advanced bowel cancer. It compares a new medicine (S95005) with an existing one (capecitabine), both given with bevacizumab. The aim is to see if the new combination works better for patients who can't have intensive chemotherapy.
Metastatic Colorectal CancerIreland - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
This study looks at two different daily pill combinations for adults newly diagnosed with HIV. It compares a two-drug treatment with a three-drug treatment to see which is safer and works better for controlling the virus.
HIVHIV InfectionsIreland - RecruitingPHASE3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
This study looks at a new drug called Tralokinumab for children and babies with moderate to severe eczema. We want to see if it's safe and helps when given with standard eczema creams. It could offer new hope for managing this condition.
Atopic DermatitisIreland - Enrolling by invitation
Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
This study is checking on men with haemophilia B who previously received a gene therapy called etranacogene dezaparvovec. It aims to understand the long-term safety and how well the treatment continues to work over time after their original studies finished.
Hemophilia BIreland - Active not recruitingPHASE3
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
This study looks at a new inhaled medicine, molgramostim, for a rare lung condition called autoimmune pulmonary alveolar proteinosis (aPAP). We want to see if it helps patients better than a dummy treatment. After 48 weeks, everyone gets the active medicine.
Autoimmune Pulmonary Alveolar ProteinosisIreland - RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
Colorectal NeoplasmsIreland - Active not recruitingPHASE3
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
This study looks at new ways to treat children with a type of blood cancer called Acute Myeloid Leukaemia (AML). It compares different chemotherapy drugs, including a drug called gemtuzumab ozogamicin, and different types of stem cell transplants to find the most effective and safest treatments for young patients.
Acute Myeloid LeukaemiaIreland - RecruitingPHASE3
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study looks at a new treatment called benralizumab for people with severe asthma. It compares adding benralizumab to your usual asthma inhaler with just increasing the dose of your inhaler. We want to see if benralizumab helps control asthma better and is safe.
Eosinophilic AsthmaIreland - Active not recruiting
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
This study looks at how well a medicine called Humira works and how safe it is for children aged 6 to 17 with Crohn's disease. It also compares Humira to other common treatments like azathioprine, 6-mercaptopurine, or methotrexate, watching patients over a long time.
Crohn's DiseaseIreland - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisIreland - RecruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic NeoplasmsIreland - Active not recruitingPHASE2
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
This study is testing a new medicine called telisotuzumab vedotin for people with a specific type of advanced non-small cell lung cancer where a protein called c-Met is present. It aims to find out who benefits most and how well it works.
Non-small Cell Lung CancerIreland